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Editorial. 
 Enhancing vaccine design strategies:  
Applications for protein science, proteomics and adjuvants. 
 
Yvonne Perrie, Helen R Griffiths and David Jones 
 
Vaccines have saved millions of lives. Currently, and for infectious diseases in humans at least, 
sanitation and vaccination remains the most efficient and the most cost-effective prophylactic 
treatment available. Vaccination has led to the global eradiation of smallpox, the virtual 
eradication of polio and a reduction of over 95 % in the incidence of diphtheria, tetanus, 
pertussis, measles, mumps and rubella [1]. Indeed, successful vaccine strategies have 
circumvented mortality caused by infectious diseases in developed countries and have thus 
increased our lifespan [1]. TŽĚĂǇ ?Ɛ ƐŽĐŝĞƚǇ ŝŶ developed countries has a life expectancy of 
more than 80 years and there is a higher proportion of elderly to young people. However, 
there remains a continued need for the development of new vaccines to offer protection for 
infections where we currently have no effective vaccine (infections such as malaria or HIV), 
and recurrent diseases (such as tuberculosis, respiratory syncytial virus, influenza A and B), 
plus newly emergent diseases, such as West Nile fever or ebola. Vaccination is also 
increasingly recognised as an important strategy for food security, by providing protection to 
livestock against existing and emerging pathogens. 
 
In developing vaccines, there is a range of options for consideration: 1) attenuated vaccines, 
where the infection is live but weakened e.g. BCG; 2) killed or in-activated vaccines, these are 
typically prepared by heat or chemical treatment and examples include influenza vaccines; 3) 
sub-unit or toxoid protein-based vaccines, e.g. HBV and 4) vaccines based on extended 
carbohydrate epitopes. These traditional approaches have proved successful, clearly evident 
by the reduction in mortality rates caused by of a number of infectious diseases. However, 
there can be numerous hurdles to consider in the selection of the vaccine platform design. 
This can include difficulty in cultivating the pathogen in vitro, as in the case with Hepatitis B 
virus (HBV) and parasites such as malaria and schistosoma. Determining that cultured 
pathogens are killed or sufficiently attenuated for safe inoculation is also of major concern. 
However, recombinant DNA technology has enabled the development of protein-based 
vaccines that can address these particular issues. Indeed, a recombinant protein of the HBV 
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surface antigen, expressed by DNA-transfected cells, has led to a human vaccine against the 
virus. Other recombinant protein vaccines are being developed and tested including those for 
tuberculosis, herpes simplex virus (HSV-1), the influenza virus as well as cancers.  
 
In recent times, prompted by several safety concerns, there has been a move away from 
whole-pathogen vaccines towards sub-unit and epitope ensemble vaccines. Sub-unit vaccines 
cannot revert to a virulent form; this is a phenomenon apparent amongst certain attenuated 
vaccines and can prompt a wide range of adverse effects, from severe morbidity to mortality. 
This can be supported further by the recent increase in knowledge and expertise in the field 
of biotechnology which opens up the ability to design new vaccines using synthetic peptides 
and proteins. Whilst these systems offer enhanced safety profiles compared to live 
attenuated systems, sub-unit vaccines tend to offer reduced potency.  To address this issue 
adjuvant systems can be exploited.   
 
To stimulate new collaborations and developments in vaccines, the British Council recently 
funded a workshop led by two organisations with complementary skills and objectives; Aston 
University in the UK, and Ho Chi Minh City Biotechnology Centre in Vietnam. This workshop 
brought together experience from protein science, biotechnology and pharmaceutical 
scientists to consider immuno-vaccinology and vaccine discovery and delivery strategies, 
using both informatics-based and experimental approaches. The workshop stimulated the 
collation of this special issue that highlights the current challenges faced in the development 
of new vaccines for human and animal welfare and outlines strategies for developing new 
vaccines.   
 
Proteomic applications are providing new insights into vaccine development [2]. The review 
by Dunston et al explores how this technology can be exploited to (a) identify novel exofacial 
antigens, (b) provide detailed information on the molecular nature of any sub-unit vaccine 
and (c) provide insight into the host response to vaccination [2]. In another powerful 
application of proteomics, the paper by Munday et al explores how the syncytial viral 
infection of epithelial cells alters expression of mitochondrial proteins in a temporal manner 
[3].  While Tom was found to be protective, hsp90 supported epithelial cell infection by virus 
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[3]. Such knowledge offers novel targets to explore in the development of anti-infective 
strategies. 
 
Within this issue, we also explore the options available for the production of sub-unit vaccines 
using yeast. Yeast offers improved yield properties and the ability to synthesise more 
challenging antigens that we have struggled to produce in other systems [4]. Indeed Nguyen 
et al., demonstrate that P. pastoris yeast can express and secrete biofunctional fusion 
proteins [5]. Cuccui and Wren [6] have reviewed how glycosylation or the modification of a 
cellular component with a carbohydrate moiety e.g. bacterial N-linked protein glycosylation 
can be exploited for glycobiotechnological applications including glycoconjugate vaccine and 
humanised glycoprotein production. The authors note that these conjugates may reduce the 
cost of vaccines thus offering further potential for glycoconjugate vaccines tailored 
specifically for animal vaccination [6]. McNair also highlights the need for improved animal 
health through vaccination [7]; drug resistance is prevalent in many ectoparasites (in human 
and domestic livestock) and new vaccines against such ectoparasites are urgently required. 
Similarly vaccines are required to protect animals against Mycoplasma mycoides-induced 
mastitis, pneumonia, arthritis, keratitis, as well as acute cases of septicaemia. In a review by 
Churchwood et al, six proteins were found to have less than 95% amino acid similarity to a 
closely related Mycoplasma species, thus demonstrating that they merit further investigation 
and evaluation in the development of diagnostic tests [8]. The challenge in developing 
effective canine infectious respiratory disease (CIRD) vaccines is also considered [9]; since 
CIRD is a complex syndrome involving a multifactorial etiology (including bacterial and viral 
pathogens) diagnosis and early treatment can be difficult and thus can affect the reduction in 
associated outbreaks. Vaccines are not available for some contributory or primary pathogens 
of CIRD and vaccination of animals during an outbreak may offer little advantage.  
 
A range of methods are being explored to enhance the delivery and efficacy of vaccines. 
Adenoviral vectors are potent inducers of T-cell and antibody responses and Coughlan et al., 
review their pre-clinical and clinical development as novel vaccine vectors [10]. When 
considering the enhancement of these vaccines through delivery and adjuvants, Walters et 
al., [11] outline the potential for developing new delivery platforms that would provide single-
shot vaccines (using encapsulation in biocompatible polymers) whilst Donnelly et al., [12] 
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have looked at applying dissolving micro-needles as a delivery platform for vaccines. To boost 
adjuvanticity, Maughan et al., [13] have outlined new developments in the use of particulate 
inorganic adjuvants and Kastner et al., [14] have looked at the development of liposomal 
adjuvants using multivariate analysis.  
 
To consider new methods for testing vaccines, Marshall et al., [15] have designed and 
characterised a multi-cellular model of human airways that takes into account the conditions 
in the airways and recapitulates many salient features, including the epithelial barrier and 
mucus secretion. This simulates the barriers to pulmonary delivery of particles and therefore 
represents a valid test platform for screening vaccines delivered via the pulmonary route. 
 
In summary, whilst there are notable success stories in the development of vaccines, key 
challenges remain. To address these and develop the next generation of vaccines it is vital for 
us to exploit the full power of modern biotechnology and computer science as key tools for 
discovering new and commercially important immunogenic antigens. These must be 
combined with safe and effective adjuvants and delivery mechanisms to ensure that we 
can develop cost-effective vaccines that are globally accessible.  
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